non-u analyst us disclosur credit suiss seek busi compani cover research report result investor awar firm may
conflict interest could affect object report investor consid report singl factor make invest decis
despit remov compani specif litig overhang revenu ep beat across board
investor cautiou head remaind
macro overhang loomvolatil expect increas head deeper elect cycl investor
cautiou us broader econom health
investor select focus event like move needl
select catalyst watch
kra updat world lung upcom weekend initi registr monotherapi
trial closest competitor plan present proof-of-concept data
regeneron potenti approv launch novarti brolucizumab octob competitor eylea
nda file ptc/roch risdiplam oral competitor spinraza phase data
howev remain posit sector reiter belief target approach invest biotech
coverag larg cap biotech
under-perform consensu call
think stock select alpha gener target therapi
examin state commerci busi
 like remain backdrop sector seller look capit premium valuat buyer
high level cash easi access capit valuabl stock use transact
drug price overhang us elect potenti reform medicar part
litig overhang remov investor focu shift futur
enbrel ip litig de-risk largest singl contributor revenu
us sale
regeneron us praluent ip litig invalid patent protect
decis maintain statu quo praluent repatha still sold us regeneron
focu pipelin replenish remain late stage commerci view favor investor
announc purchas otezla manag guid growth consensu expect
investor posit near-term accret deal
gilead/galapago gilead significantli expand term galapago partnership pay access
transact tax-effici less expens full take-out
contrast share continu declin despit large-scal share repurchas expect futur
competit ms sma highlight urgent need transact revenu growth
continu execut across coverag univers
cover commercial-stag compani beat consensu revenu ep expect
notabl strong perform vertex neurocrin
regeneron/sanofi collabor profit ahead previou guidanc
pipelin progress continu ahead earlier expect
gilead/galapago announc file filgotinib investor previous expect need long-term safeti studi
made steadi progress biosimilar saw launch mvasi kanjinti us posit top-lin data
abp ipr proceed initi alexion soliri support abp
despit solid biotech sector continu under-perform
charl martineau pm univers toronto lc stock recov highs/low late
earli investor seem cautiou approach
multipl forward p/e larg cap biotech set potenti buy opportun
sentiment around larg cap seem poor concern drug price growth macro trend
sentiment around smid cap better specialist posit around catalyst
valuat still rel near all-tim high acquisit premium higher ever
charl martineau pm univers toronto return versu inconsist
past year uneven return front half back
half year
look toward sever import issu investor mind could
strong impact sentiment potenti drug price legisl presidenti
elect invert yield curv specul slow economi
charl martineau pm univers toronto biotech under-perform sinc boom
gone day buy basket major biotech name gener alpha
believ investor still find upsid discern
view exposur biotech focu target select approach pick stock
approach analyz sector
charl martineau pm univers toronto coverag univers glanc
consensu
charl martineau pm univers toronto target therapi roadmap find alpha
break compani three area analysi
charl martineau pm univers toronto target therapi portfolio overview coverag
total revenu
total revenu
total revenu
total revenu
total revenu
total revenu
total revenu
total revenu
buyer strength
buyer weak
buyer weak
buyer strength
 strength
net
 strength
net
buyer strength
 strength
net
 strength
net
 strength
nm net
total revenu
total revenu
total revenu
total revenu
total revenu
total revenu
total revenu
total revenu
total revenu
total revenu
regeneron pipelin revenu gener subject collabor profit share agreement increment end-us sale necessarili get book revenu regeneron
vertex differenti growth profil expect drive near-term cash flow also allow reinvest
busi support long-term growth think continu commerci execut pipelin updat guidanc
revis support share rel peer expect updat file full data set tripl
combin therapi well continu progress toward reimburs uk franc rest world drive
proprietari work support thesi separ model uk franc opportun scenario analysi
neurocrin commercial-stag biotechnolog compani two market asset ingrezza tardiv dyskinesia td
orilissa endometriosi em market partner think ingrezza best-in-class treatment td
expect drive revenu earn growth next year see underappreci upsid potenti
pipelin focus central nervou system asset parkinson diseas opicapon gene therapi
congenit adren hyperplasia among smid-cap coverag neurocrin top pick due project strong revenu
growth name ingrezza addit revenu stream orilissa solid pipelin favor risk/reward
proprietari work support thesi support expert physician discuss
view attract rel peer underappreci biosimilar busi could help chang project base busi
revenu declin rel stabil vs large-cap peer vari promis pipelin novel asset oncolog immunolog
compel valuat good balanc return capit sharehold repurchas dividend pipelin potenti abil yet
urgent need
think recent gilead transact good deal galapago allow glpg realiz much valu earlier stage pipelin
de-risk clinic trial beyond filgotinib think blockbust potenti ipf oa could
interest asset well given larg address market healthi cash posit experienc collabor gilead see
favor risk/reward updat filgotinib toledo expect potenti driver upsid
aimmun current leader treatment peanut allergi late-st asset believ oral immunotherapi
like approv therapi reduc risk accident exposur children adult peanut allergi competitor aimmun
dbv least one year behind follow voluntari withdraw bla competit product viaskin peanut decemb
overal expect share continu outperform get closer launch expect late earli beyond
peanut allergi aimmun also pursu develop treatment egg allergi
neutral rate predic three main issu like base hiv busi see outsiz growth would significantli alter
earn project cell-therapi import platform sale yescarta unlik gener revenu akin sovaldi/harvoni
unlik under-perform think forward price-to-earnings multipl somewhat protect contract howev new
strateg vision acquisit could see expans
begun find way back pipelin execut failur epacadostat howev need clinic evid trial
execut pipelin posit stock like jakafi franchis revenu growth profil see opportun fairli
valu find difficult point specif pipelin asset high convict clinic commerci perspect rel
smid-cap peer rate neutral think better pipelin risk/reward commerci busi upsid elsewher
whole view current valuat busi fair like compani focu innov expans pipelin
concern eylea could face increas headwind upcom launch novarti brolucizumab consensu forecast sanofi
collabor may high estim seem overst collabor profit
eptinezumab approv could face strong headwind fourth-to-market drug rel undifferenti clinic data method
administr howev project eptinezumab could still captur market share brand adopt like determin mainli payer
life beyond aducanumab like remain challeng base busi like declin near term weak pipelin
like abl yield revenu earn growth ms expect increasingli competit major spinraza revenu
risk competit anticip signific share loss new sma spinal muscular atrophi incid novarti zolgensma long-term
believ ptc/roch risdiplam could take signific share preval sma market alzheim longer around focu investor
attent base busi eros like drive downsid manag priorit share repurchas could lead
multipl compress
proprietari work support thesi ms physician survey illustr scenario analysi spinraza franchis scenario analysi
charl martineau pm univers toronto macro theme
charl martineau pm univers toronto rise ahead possibl downturn
 usual remain constant backdrop larg cap biotech usual buyer smid cap
seller think pipelin hole need growth main driver key talk point
remaind seller may look realiz premium valuat ahead potenti
although valuat come high takeout premium continu rise
deal
charl martineau pm univers toronto view potenti buyer target coverag
buyer strength
buyer weak
and/or need
and/or need
net
net
net
net
net
although posit neurocrin potenti
acquisit target could see compani engag
smaller buyer busi develop
broaden respect pipelin
estim deal capac base analysi current cash balanc debt capac project
next year account announc share repurchas
charl martineau pm univers toronto drug price health polici legisl unlik
drug price like overhang elect
see limit progress topic near term given split control hous senat
white hous
like see hh institut rebat reform medicar part plan
polici expert believ pbm stand lose rebat reform
compani abl reli less price increas drive revenu growth long term
current idea medicar part reform
reduc percent mark-up appli addit reimburs tie drug cost
propos yet implement
industri skeptic
part could close resembl part reimburs
privat insur compani would negoti directli manufactur use rebat tier
therapeut administ office/hospit set
solv issu rebat
part reformpropos rebat rule withdrawn juli
expect discuss shift back toward implement
gener track
phase clinic data asco
judg decis court case
district court decis perman
injunct follow second juri trial
novarti approv zolgensma
novarti approv brolucizumab
phase data eha
submiss eu
fxr
phase data like
esmo tripl
mylan ipr decis patent
updat uk franc
charl martineau pm univers toronto company-specif overview tear sheet
file fda
top-line data tripl
fda approv symdeko
review
vertex revenu exceed consensu expect
although lower perform
larg expect given tradit lower sale
growth driven primarili symdeko uptak us
launch symkevi germani
vertex execut key catalyst mainli
tripl combin support compani
effort treat cf patient approv drug could treat
cf patient would allow vertex even
stronger command market compani also continu
expand pipelin strateg partnership
outperform rate base view vertex differenti
growth profil drive near-term cash flow also allow
reinvest busi support long-term growth think
continu commerci execut pipelin updat guidanc revis
support share rel peer expect updat file full
data set tripl well continu progress toward reimburs
uk franc rest world drive upsid
next month expect continu progress
commerci front cf development updat tripl
potenti updat earlier pipelin continu commerci
execut main-driv near-term upsid view detail
surround regulatori file tripl decis tripl
combin bring forward full data set potenti fall
nacfc meet could also support stock beyond cf updat
potenti initi data patient treat could provid
share price appreci
reimburs agreement england franc
continu penetr market rest-of-world under-
appreci revenu opportun like drive upsid uk
largest concentr cf patient world approxim
world popul thu repres
signific revenu opportun formal agreement franc would
also like drive share upsid predict exactli
agreement would reach think recent progress vertex
uk govern posit indic
one-year price target base base-cas risk-
adjust dcf analysi assign po tripl
combin likelihood reimburs deal uk
franc
buyer strength
vrtx price-to-earnings high
support upsid
ou reimburs
compani still earli stage
ratio large-cap
biotech peer pharma
vertex gain broad reimburs
tougher govern particularli uk
franc
vertex price-to-earnings high warrant
continu multipl expans cash-
flow earn potenti fairli
vertex continu experi
difficulti obtain ou
reimburs fail reach
agreement uk franc
valuat non-cf
vertex diversifi pipelin high-
valu therapeut area like
gener near-term share upsid
like posit data updat
pipelin beyond cf immatur
like over-valu market
vertex best earn revenu growth
profil among large-cap biotech pharma
high price-to-earnings function recent becom
profit basi rel cost
earn growth far less peer
follow recent interact uk parliament
think agreement nh get
closer agreement would provid upsid
revenu uk franc essenti
near-term thesi
non-cf pipelin free call option limited-
to-no valu ascrib pain crispr
gene-edit updat initi recruit dose
molecul select nda file
ingrezza beat
opicapon nda file
elagolix snda file uterin
review
tradit softer due season saw strong
out-performance record number new patient
addit improv refil rate yoy
growth start see benefit expand
forc compani
neurocrin deliv expect complet regulatori
file pipelin asset opicapon elagolix compani
collabor voyag like reinvest
execut pipelin de-risk relianc ingrezza
neurocrin commercial-stag biotechnolog compani two market asset ingrezza tardiv
dyskinesia td orilissa endometriosi em market partner think ingrezza
best-in-class treatment td expect like drive revenu earn growth next
year see underappreci upsid potenti central nervou system focus pipelin asset
parkinson diseas opicapon gene therapi congenit adren hyperplasia among smid-
cap name neurocrin top pick due project strong revenu growth name ingrezza
addit revenu stream orilissa solid pipelin favor risk/reward
ingrezza best-in-class therapeut td blockbust
potenti think on-going launch ingrezza like
remain strong forecast potenti sale earli
vari pipelin favor risk/reward neurocrin pipelin
asset stage develop pre-clin phase
like option asset note like fda
approv opicapon pivot studi begin
accord compani updat recent
ink gene-therapi partnership voyag
orilissa could market leader endometriosi
uterin fibroid given unmet medic need first-to-
market posit market believ could
receiv consider royalti revenu long-term label
expand uterin fibroid
one-year price target base base-cas risk-adjust
dcf analysi assign po opicapon nbi-
orilissa uterin fibroid
 strength
net
ingrezza tardiv
orilissa endometriosi
uterin fibroid
upsid potenti
pipelin
differenti competit
market penetr provid long term
upsid strong share acquisit
orilissa could potenti second-
line treatment choic moderate-to-
sever em due similar efficaci
greater conveni fewer side
opicapon could therapi
choic levodopa extend
provid addit upsid market
signific unmet need
neurocrin may fail increas physician
decreas payer restrict may
hamper growth usag
increas competit relugolix
sale due undifferenti therapi
gnrh antagonist market
long-term use opicapon could prove
unsaf smaller expect
uptak could occur due ineffect
commerci earli
stage minim support data
ingrezza continu revenu growth driver
neurocrin due superior profil simplifi
dose titrat believ
better safeti profil believ consensu
estim conserv
efficaci data elagolix relugolix linzagolix
rel similar clear favorit exist
market larg enough three player clinic
adopt like base superior market
formulari adopt drive brand prefer
opicapon potenti best-in-
class comt inhibitor proven efficaci
toler side effect conveni dose
rel drug class competitor posit
data provid confid
fda meet adult pivot studi
posit clinic data
asco
kanjinti mvasi us launch
win litig
review
produc solid quarterli revenu
although out-performance driven mainli via posit
 kra data enbrel rule
enbrel win secur exclus decis remov
big overhang stock de-risk base busi
reli heavili enbrel end expect investor
get back stock
phase data kra suggest clinic efficaci
could support eventu regulatori approv
mvasi kanjinti launch us highlight grow
biosimilar businesson part long term strategi believ
could address slow base busi
attract rel peer underappreci biosimilar busi could help chang project base busi revenu
declin rel stabil vs large-cap peer vari promis pipelin novel asset oncolog immunolog compel
valuat good balanc return capit sharehold repurchas dividend pipelin abil yet urgent need
thesi grow biosimilar busi
view anchor next leg revenu growth even base busi
declin see potenti global gener sale
view franchis help mitig replac lost
revenu current base busi
oncolog pipelin amgen novel oncolog pipelin price
could provid signific addit upsid clinic data readout
harder quantifi like broad oncolog platform asset
address high-valu target area unmet medic need updat
oncolog pipelin could provid sourc upsid catalyst
near mid-term
price discount current trade price-to-earnings discount
 vs ep factset estim major pharma
peer merck lilli slow
eros base busi well known potenti
repres current valuat
note figur may sum total due round credit suiss estim
one-year price target base base-cas risk-adjust
dcf analysi assign po pipelin biosimilar
mvasi
buyer strength
stock
expens rel
rel expens
base busi trade
in-lin large-cap peer
think trade least in-lin
major pharma slight premium given
underappreci biosimilar busi upsid
asthma broad novel oncolog pipelin
trade higher forward
earn multipl peer
pharma peer
expect biosimilar busi
aimovig novel oncolog pipelin
fulli reflect estim
even tezepelumab could
could see posit data
tezepelumab
asthma omecamtiv mecarbil
evolut
upsid potenti
pipelin
eros base busi
appreci street launch
aimovig also strong expect
furthermor unabl
pipelin failur continu compress
multipl stock begin
trade discount biotech
project similar declin base busi vs
consensu howev biosimilar could
make revenu declin base busi
potenti revenu aimovig even
diversif heme-onc
addit car-t asset
phase clinic data asco
present asco
decis court case vs sandoz
decis praluent patent infring
phase updat lung data iaslc
review
submiss eu although
rel quiet await
adcom fda
trade thought expect volatil share
surround adcom septemb given binari natur
event decis could strong implic share price
aimmun current leader peanut allergi treatment space late-st asset given current clinic data set believ
oral immunotherapi like approv therapi reduc risk accident exposur children adult peanut
allergi competitor aimmun dbv therapeut least one year behind follow voluntari withdraw bla
competit product viaskin peanut decemb overal think share continu outperform get closer launch
expect late earli beyond peanut allergi aimmun also pursu develop treatment egg
view aimmun rel biotech peer
aimmun current revenu commerci
begin next year expect gener
revenu compani unadjust potenti sale
product revenu
 perspect believ aimmun
acquisit target posit strength
asset like approv near-term
compani could acquir prior approv shape
commerci trajectori asset
risk clinic development lead asset
regulatori fda/ema may approv
product commerci much valuat base
futur sale supplier aimmun reli
singl supplier peanut protein external/ market
biotech remain volatil sector could impact
one-year price target base base-cas risk-adjust
dcf analysi assign po
departur gilead cso john
descovi prep adcom
filgotinib allow file without
review
begin see vision outlin new ceo
oday play acceler throughout past
month far oday kept word sinc
earn call work fda move filgotinib forward
without need manta trial data like provid
clariti need make deal galapago
believ significantli expand pipelin beyond hiv made
key manag chang kite gileadsignifi
new direct compani
gilead also experienc failur nash franchis
selonsertib miss primari endpoint although failur
could attribut prior regim
outlook neutral three main reason like base hiv busi see outsiz growth would significantli alter earn
project cell-therapi import platform sale yescarta like never gener revenu akin sovaldi/harvoni
unlik under-perform think multipl somewhat protect contract new strateg
vision acquisit could see expans
multipl unlik contract rel
peer pay growth gilead share trade warrant
forward price-to-earnings discount larg cap biotech peer think hiv
hcv fairli valuedeven dominant-shar hiv like
continu per physician check proprietari survey yescarta
cell therapi franchis repres interest innov howev
continu believ commerci remain challeng
past readout fairli confid
filgotinib leader immunolog space follow posit
data see limit downsid risk current trade level howev
pend clariti stori evolv back growth
expect signific multipl expans near term
strong strateg prioriti yet wait execut first
glimps oday earn call got sens
understand urgenc fill later-stag pipelin submit market
applic filgotinib soon possibl focu commerci
deliveri think right strateg approach
commerci front think effort acceler sale yescarta
would seen posit think formal separ kite
distinct busi unit could help foster innov akin roch
handl genentech
one-year price target base base-cas risk-adjust
dcf analysi assign blend po filgotinib across
multipl indic valu on-going nash program
buyer weak
durabl hiv
gilead continu remain domin
player hiv busi driven
biktarvi gener unabl dent
sale durabl growth viiv
yescarta beat expect driven
manufactur improv label
next-gen therapi kite
allogenic-bas platform
daniel oday abl success
navig gilead top bottom-lin
earn growth intern restructur
acceler cell-therapi
franchis extern
gilead market share heavili impact
brand gener competit
greater-than-expect uptak
patient less expens option
yescarta sale continu lag gilead
unabl expand current pi
yescarta gilead unabl develop
cell therapi forc write
kite acquisit
daniel oday big-pharma style
leadership clash gilead biotech
mental deliv
reacceler revenu earn
expans cell
phase data present
phase data present
phase data present
data phase phase pivot studi
data phase
data phase
submiss eu
data registr phase studi
dlbcl mab data phase combin studi
complet enrol pivot phase
nda file us
per physician check survey believ
gilead remain domin hiv gener impact
limit us in-lin expect
ou limit impact viiv doublet survey
believ yescarta sale continu
modest minim expans
indic due strong competit long
run kite platform could import
gilead though hard justifi price
given oday track record roch believ
effect leader get
sens appreci urgenc bolster
later-stag pipelin look see
execut strategi recent outlin
posit capmatinib data asco
fda approv jakafi steroid-
posit topic ruxolitinib data
vitiligo wcd
review
continu recov well epacadostat failur
compani deliv sever promis includ
posit data topic ruxolitinib capmatinib also
expand ruxolitinib steroid-refractori gvhd view
steroid-nav market gvhd repres larger opportun
itacitinib steroid-refractori gvhd ruxolitinib
also like capmatinib limit econom
drug view topic ruxolitinib much larger opportun
could interest option commerci
estim unadjust sale
begun find way back pipelin execut failur epacadostat howev need clinic evid trial
execut pipelin posit stock like jakafi franchis revenu growth profil think opportun
fairli valu find difficult point specif pipelin asset high convict clinic commerci perspect
rel smid-cap peer rate neutral think better pipelin risk/reward commerci busi upsid elsewher
jakafi franchis drive growth
estim sale yet flow fairli
valu debat strength jakafi franchis
like remain best-in-class inhibitor two rare blood
cancer also think clinic data seen thu far
itacitinib steroid-nav graft vs host diseas gvhd compel
believ opportun much smaller jakafi rare blood
oncolog pipelin vari yet bulk clinic data
immatur meaning valuat rebuild pipelin
oncolog rel strong view think mani
asset earli meaning valuat pemigatinib
shown efficaci rare bile-duct cancer opportun appear
modest would compet larger bladder
dermatolog franchis may better posit out-
licens asset topic ruxolitinib could effect treatment
varieti immune-medi dermatolog condit think
could out-licens asset sell topic dermatolog
drug differ vs oncolog could unlock valu
bolster oncology-focus pipelin
one-year price target base base-cas risk-adjust
dcf analysi assign po jakafi gvhd
pemigatinib cholangiocarcinoma po topic ruxolitinib
po itacitinib gvhd pemigatinib bladder cancer
 strength
net
expect
opportun
multipl shot goal
mani focu
diversif
jakafi well posit mf
pv space like upsid
steroid-refractori gvhd itacitinib also
well posit take share
asset pemigatinib fgfr
mutat tumor capmatinib
nsclc could drive next leg
growth despit prior failur
provid interest upsid given
believ grow atop
dermat market unmet need
limit upsid exit jakafi mf
pv gvhd opportun
smaller compani street
expect itacitinib opportun also
smaller expect
market pemigatinib small
cholangiocarcinoma furthermor drug
face competit js balversa
bladder cancer capmatinib entitl
royalti novarti
develop dermatolog asset
distract incyt organ
core oncolog focu
baricitinib like limit usag ad
think jakafi solid drug like
reach us peak sale yet think
upsid fairli valu believ market
like smaller expect gvhd jakafi
itacitinib
like pemigatinib drug face competit
econom capmatinib control
novarti like multipl shot goal think
oncolog pipelin rel immatur
warrant higher valuat current assign
dermatolog franchis best posit
out-licens opportun core
compani current oncolog focu baricitinib
viabl ad asset given toxic
emerg competit landscap ad
nda submiss novarti geometri
phase data present breeze-ad like eadv
eylea approv fda diabet
dupix approv ec
patient year older
asthma patient year
ad
dupix approv fda
review
share gener trade line ibb
howev stock larg under-perform
start fda accept novarti brolucizumab april
eylea enjoy posit market leader vs
lucenti off-label avastin think brolucizumab could
seriou disruptor eylea franchis
on-going launch dupix key driver sanofi
collabor continu deliv saw label expans
throughout dupix crswnp age expans
ad asthma sanofi collabor beat
expect support label expans
think whole current valuat fairli valu busi like compani focu innov expans pipelin
concern eylea could face increas headwind upcom launch novarti brolucizumab sanofi collabor consensu
forecast may high estim seem overst collabor profit
eylea growth expect slow market satur
competit novarti expect earli
eylea enjoy posit marker leader think
near-term launch novarti brolucizumab could disruptor
assum share loss wamd chang way
medicar part drug reimburs could impact eylea sale
significantli eylea highest total spend product
could see shift reimburs part even usag
intern price index price think substant polici
chang unlik highlight risk
long-term consensu expect dupix
revenu sanofi collabor may high
proprietari survey indic physician enthusiasm dupix
asthma long-term revenu number like account
competit asthma see potenti competit
amgen/astrazeneca tezepelumab show impress
efficaci phase ad expect competit novel jak
inhibitor may safer previou gener consensu
collabor revenu forecast view unrealist high
forecast collabor revenu constant issu
given complex partnership limit visibl
profit driver revenu miss
one-year price target base base-cas risk-adjust
dcf analysi assign po dupix nasal polyp
eoe libtayo nsclc cervic cancer
buyer strength
end-us sale subject collabor profit share agreement
necessarili book regeneron revenu
eylea continu grow despit
take minim share launch
dupix second flagship asset
regeneron truli pipelin within
ad asthma nasal polyp eoe
minim competit
libtayo strong gateway asset io
regeneron cscc small
could see addit upsid
indic collabor
pipelin asset provid upsid
eylea sale strongli impact
share biosimilar also impact usag
eylea physician payer opt
less-expens altern
sale dupix fail acceler due
competit threat ad asthma
mix data nasal polyp eoe
limit upsid opportun drug
libtayo sixth
approv small indic
regeneron sanofi miss
boat io allianc
see slow eylea growth due market
satur potenti launch competitor
forecast consensu sale beyond
brolucizumab biosimilar moder
impact eylea sale go forward
dupix differenti drug ad
asthma consensu expect like
high behind
dupix see competit novel jak
inhibitor ad tezepelumab asthma
libtayo could produc least sale
across cscc cervic basal cell
carcinoma data
encourag cautious optimist
bcma collabor program
pdufa approv wamd novarti
review
file fda accept
posit data present eptinezumab
philadelphia may
show rapid onset migrain prevent
initi phase studi eptinezumab acut migrain
adcom fda
trade thought expect modest volatil aldr
share surround adcom februari given binari
natur event decis could strong implic
share price view posit outcom larg expect
alder clinic stage biopharmaceut compani focus treat migrain headach novel therapeut antibodi
compani lead asset eptinezumab intravenously-administ calcitonin gene-rel peptid cgrp ligand inhibitor like
approv chronic migrain prevent set pdufa eptinezumab approv could face strong
headwind fourth-to-market drug rel undifferenti clinic data method administr howev project
eptinezumab could still captur market share brand adopt like determin mainli payer coverag
view alder rel biotech peer
alder face competit three market drug
alreadi broad patient adopt
clinic efficaci iv administr rel
undifferenti market competitor
uptak like determin payer coverag
therefor could see drug maker potenti increas
discount gain maintain coverag market
becom competit
clinic development lead asset eptinezumab
commerci major valuat base futur sale
regulatori fda may approv product
external/market biotech remain volatil sector
one-year price target base base-cas risk-
adjust dcf analysi assign po eptinezumab
phase failur aducanumab
ipr proceed begin
novarti zolgensma approv
share repurchas
review
aducanumab longer around focu investor attent
commerci busi develop pipelin capit
alloc strategi come greater scrutini
despit large-scal share repurchas biogen
share continu subject multipl contract
commerci busi seen increas level risk
due mylan ipr tecfidera launch zolgensma
impend file risdiplam sma
view pipelin asset like move
needl signific portion base busi revenu
risk think multipl compress possibl capit
deploy continu priorit share repurchas one-
time accret invest long-term growth via bd
life beyond aducanumab like remain challeng base busi like declin near term weak pipelin
like abl yield revenu earn growth ms expect increasingli competit major spinraza revenu
risk competit anticip signific share loss new sma incid novarti zolgensma long-term believ ptc/roch
risdiplam could take signific share preval sma market alzheim longer around focu investor attent base busi
eros like drive downsid manag priorit share repurchas could lead multipl compress
unclear path forward aducanumab failur face
believ clear challeng establish execut
strateg path forward past year share price
close tie increment updat alzheim diseas ad think
without ad program growth stori remain
murki meaning de-risk pipelin asset recent
manag commentari indic priorit share
repurchas expect multipl compress
greater proport cash flow return sharehold rather
reinvest growth
major spinraza revenu risk competit
see direct competit novartiss gene therapi product zolgensma
could use primari treatment newli diagnos patient
replac ahead biogen spinraza gene therapi could
differenti single-tim dose compar chronic administr
spinraza think spinraza incid market newli
diagnos patient type sma like shift zolgensma
especi on-going implement newborn screen sma
long-term preval market risk roche/ptc
risdiplam believ oral option would strongli prefer
intrathec inject given compar efficaci view
revenu risk zolgensma risdiplam under-appreci
one-year price target base base-cas risk-adjust
dcf analysi assign po vumer ms base
case assum spinraza lose major share sma
incid market zolgensma split remain
preval opportun risdiplam
buyer weak
competit sma
see upsid spinraza
despit gene therapi launch
success pipelin continu
durabl ms franchis despit
competit zolgensma less
anticip risdiplam either fail trial
significantli less efficaci
spinraza sale peak
remain durabl long term
success across near-term pipelin
pain vixotrigin nightstar asset
posit pipelin updat continu
face headwind across
commerci busi sma ms
biosimilar pipelin bd effort fail
re-acceler growth lead
multipl compress
zolgensma abl take nearli
entir share newli diagnos infant
driven newborn screen risdiplam
replac spinraza standard-of care
preval market
near-term pipelin fail deliv
revenu growth either due failur
clinic commerci under-perform
forc write
nightstar purchas
impact headwind across base busi
magnifi investor littl els focu near-
term despit view urgent need acquir
growth manag recent emphas belief
share repurchas best use capit
believ full impact lose
incid market bake number
risdiplam shown good efficaci thu far
potenti replac spinraza preval
market especi sma type
believ current pipelin
drive upsid asset highlight compani
limit data unsuccess trial
nightstar asset like small market
meaning affect
mylan ipr decis patent
charl martineau pm univers toronto allergi immunolog market remain immatur
atop dermat asthma
market
dermat
regeneron dupixentasthma
suggest dupix
compel efficaci safeti
dermat vitiligo
compel therapi review
compel therapi review
safeti advers event data
respond
respond
charl martineau pm univers toronto novel oncolog pois address difficult-to-treat tumor
type extend life reduc burden cancer
broad pipelin address high valu target
bispecif target bcma multipl myeloma
increment sale per asset
differ approach car-t
regeneron potenti leverag across multipl
libtayo market cutan small cell
carcinoma seek approv non-smal
bispecif target bcma ovarian
gilead car-t innov franchis field
increasingli competit slow uptak
still play catch epacadostat failur
oncolog market expect grow
driven mainli merck bristol
growth driver
still expect see increas use
addit approv car-t bispecif
charl martineau pm univers toronto novel neurosci therapi progress
ingrezza tardiv dyskinesia key revenu driver
ingrezza could reach peak sale
pipelin diversif gene therapi
collabor voyag therapeut
multipl sclerosi franchis remain core
compon base busi near term long-
term headwind exist novarti mayzent
celgen ozanimod roch ocrevu
satisfact use treatment-
experienc patient share captur
biogen tysabri inject
sma biogen remain leader expect
signific competit novarti zolgensma
roche/ptc risdiplam bull/base/bear
case present next slide
charl martineau pm univers toronto migrain renew focu recent launch cgrp
aimovig remain leader despit crowd
commerci landscap anti-cgrp market
slower growth compar competitor
clear competit edgeclin data
competit threat oral cgrp
payer coverag still biggest hurdl
pbm
payer coverag cgrp
market share
charl martineau pm univers toronto gene therapi gene edit leader coverag
program could provid pipelin upsid near term
none coverag
nightstar acquisit interest
see difficulti commerci
headwind novarti zolgensma gene
therapi biogen spinraza sma
vertex crispr partnership sickl cell
diseas beta thalassemia earli stage
first patient dose februari
potenti competit bluebird bio
pipelin diversif data still earli
friedreich ataxia earlier lead candid
expect
first patient parkinson diseas indic
high consensu estim revenu growth
look deal space given
focu person medicin
expect continu invest could see
even clinic data across indic
charl martineau pm univers toronto biotech becom less expens forward price-to-earnings basi
forward price-to-earnings larg cap biotech vs us pharma
biotech
lower
price-to-earnings
lower
price-to-earnings
factset larg cap biotech celg note year exclud vertex due period net loss per share us
charl martineau pm univers toronto investor appetit biotech still exist ipo ytd
ipo
pd-gba neuronopath
charl martineau pm univers toronto investor appetit biotech still exist ipo ytd
ipo
barth lhon
nmibc pancreat ovarian
charl martineau pm univers toronto short interest larg cap biotech coverag
short interest larg cap biotech
regeneron highest short interest larg cap coverag
gilead lowest
neurocrin highest short interest
lower
aimmun short interestth highest coverag
high fund outflow
less fund flow past month
charl martineau pm univers toronto credit suiss coverag univers valuat
charl martineau pm univers toronto credit suiss us larg cap biotech approach analysi
look
fundament underappreci mischaracter opportun
properli identifi quantifi address market
access factor
profit organiz structur measur via cash flow earn growth
abil deploy capit drive growth despit broader industri headwind via
organ innov support well-character biolog organiz expertis target unmet need
strateg synergist accret busi develop bd yield return buyer target
visibl achiev path realiz valuat target
catalyst strong impact predict time
proprietari research analys support these
charl martineau pm univers toronto credit suiss us larg cap biotech approach valuat
think valuat
target price deriv risk-adjust product-specif sum-of-the-part discount cash flow
analysi alloc d/sg expens plu pipelin unalloc expens
assign probabl success base standard success rate literatur de-risk previou stage
specif program indic trial
forecast cash flow least year account impact known identifi competit patent
expir product launch beyond forecast period assess termin valu account organiz
capabl replac cash flow lost eros
discount rate base stage develop stage pre-clin earli late clinic commerci
compani assess risk achiev forecast
termin growth rate base assess busi end forecast period compani
abil replac cash flow lost eros
rare use multiples-bas valuat account chang busi length forecast
charl martineau pm univers toronto compani mention price
